A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.

A phase I trial was conducted with lobaplatin (D-19466; 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate) i.v. bolus daily for 5 days every 4 weeks. After entering five patients toxicity appeared to be related to renal function, therefore the individual dose (total dose 20-100 mg m-2 over 5 days...

Descripción completa

Detalles Bibliográficos
Autores principales: Gietema, J. A., de Vries, E. G., Sleijfer, D. T., Willemse, P. H., Guchelaar, H. J., Uges, D. R., Aulenbacher, P., Voegeli, R., Mulder, N. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968188/
https://www.ncbi.nlm.nih.gov/pubmed/8431374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968188/
https://www.ncbi.nlm.nih.gov/pubmed/8431374

Ejemplares similares